LGND (STOCKS)
Ligand Pharmaceuticals Inc.
$181.650000
-4.310000 (-2.32%)
Prev close: $185.960000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Todd Christopher Davis
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $3,558.65M
- Employees
- 68
- P/E (TTM)
- 87.43
- P/B (TTM)
- 3.76
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
5
Strong Buy
8
Buy
1
Hold
0
Sell
Recent News
No recent news found for this ticker.
Financial Statements
| Revenues | $251.23M |
| Benefits Costs and Expenses | $188.25M |
| Costs And Expenses | $188.25M |
| Nonoperating Income/Loss | $45.46M |
| Operating Expenses | $233.71M |
| Research and Development | $82.10M |
| Other Operating Expenses | $151.62M |
| Operating Income/Loss | $17.52M |
| Income/Loss From Continuing Operations After Tax | $48.58M |
| Income/Loss From Continuing Operations Before Tax | $62.98M |
| Income/Loss From Equity Method Investments | -$7.06M |
| Income Tax Expense/Benefit | $14.40M |
| Net Income/Loss | $48.58M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | $48.58M |
| Net Income/Loss Available To Common Stockholders, Basic | $48.58M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | $2.32 |
| Diluted Earnings Per Share | $2.05 |
| Basic Average Shares | 39,066,000 |
| Diluted Average Shares | 39,604,000 |
| Assets | $1.48B |
| Current Assets | $753.92M |
| Inventory | $11.90M |
| Other Current Assets | $742.02M |
| Noncurrent Assets | $722.85M |
| Fixed Assets | $3.47M |
| Intangible Assets | $233.54M |
| Other Non-current Assets | $485.85M |
| Liabilities | $526.60M |
| Current Liabilities | $30.54M |
| Accounts Payable | $3.68M |
| Wages | $3.70M |
| Other Current Liabilities | $23.16M |
| Noncurrent Liabilities | $496.06M |
| Equity | $950.17M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $950.17M |
| Liabilities And Equity | $1.48B |
| Net Cash Flow From Operating Activities | $31.92M |
| Net Cash Flow From Operating Activities, Continuing | $31.92M |
| Net Cash Flow From Investing Activities | -$397.84M |
| Net Cash Flow From Investing Activities, Continuing | -$397.84M |
| Net Cash Flow From Financing Activities | $440.28M |
| Net Cash Flow From Financing Activities, Continuing | $440.28M |
| Exchange Gains/Losses | $1.40M |
| Net Cash Flow | $75.76M |
| Net Cash Flow, Continuing | $74.36M |
| Comprehensive Income/Loss | $56.16M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | $56.16M |
| Other Comprehensive Income/Loss | $56.16M |